 | • レポートコード：MRC2301E022 • 出版社/出版日：Persistence Market Research / 2022年10月4日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,140,000 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,590,000 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料は、世界の膀胱がん治療薬市場について総合的・多面的に調査しています。本資料では、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、需要分析・予測、価格分析、市場背景、種類別（筋層非浸潤性膀胱がん、筋層浸潤性膀胱がん）分析、用途別（低悪性度腫瘍、高悪性度腫瘍）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア太平洋、中東・アフリカ）分析、構造分析、競争分析、仮定、調査方法などを整理しております。また、GlaxoSmithKline plc、Novartis International AG、Sanofi S.A、Pfizer Inc.、Eli Lilly and Co、AstraZeneca plc、Bristol-Myers Squibb、F., Celgene Corporationなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・需要分析・予測 ・価格分析 ・市場背景 ・世界の膀胱がん治療薬市場規模：種類別 - 筋層非浸潤性膀胱がんにおける市場規模 - 筋層浸潤性膀胱がんにおける市場規模 ・世界の膀胱がん治療薬市場規模：用途別 - 低悪性度腫瘍における市場規模 - 高悪性度腫瘍における市場規模 ・世界の膀胱がん治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他の市場規模 ・世界の膀胱がん治療薬市場規模：地域別 - 北米の膀胱がん治療薬市場規模 - 中南米の膀胱がん治療薬市場規模 - ヨーロッパの膀胱がん治療薬市場規模 - 東アジアの膀胱がん治療薬市場規模 - 南アジア太平洋の膀胱がん治療薬市場規模 - 中東・アフリカの膀胱がん治療薬市場規模 ・構造分析 ・競争分析 ・仮定 ・調査方法 |
Bladder Cancer Treatment Drugs Market: Report Scope
The latest market report by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.
The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Bladder Cancer Treatment Drugs. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.
This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global bladder cancer treatment drugs market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.
The study is relevant for manufacturers, suppliers, distributors, and investors in the bladder cancer treatment drugs market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.
Key Market Segments
Persistence Market Research’s report on the global bladder cancer treatment drugs market offers information divided into four segments – type, application, distribution channel, and region.
Type
Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Application
Low-Grade Tumors
High-Grade Tumors
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others
Region
North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa
Key Questions Answered in Study
Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global bladder cancer treatment drugs industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global bladder cancer treatment drugs market?
Research Methodology
Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global bladder cancer treatment drugs market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.
A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.
This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions – North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.
Our main sources of research include:
Primary Research
Secondary Research
Trade Research
Social Media Research
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Strategic Promotional Strategies
5. Global Bladder Cancer Treatment Drugs Market Demand Analysis 2017–2021 and Forecast, 2022–2032
5.1. Historical Market Volume (Tons) Analysis, 2017–2021
5.2. Current and Future Market Volume (Tons) Projections, 2022–2032
5.3. Y-o-Y Growth Trend Analysis
6. Global Bladder Cancer Treatment Drugs Market – Pricing Analysis
6.1. Regional Pricing Analysis By Type
6.2. Global Average Pricing Analysis Benchmark
7. Global Bladder Cancer Treatment Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Industry Value Added Overview
8.1.3. Global Infrastructure Investment Overview
8.1.4. Global Construction Spending Analysis
8.1.5. Other Macro Economic Factors
8.2. Forecast Factors – Relevance & Impact
8.2.1. Top Companies Historical Growth
8.2.2. GDP Growth forecast
8.2.3. Construction Industry forecast
8.2.4. Distribution Channel Growth Outlook
8.2.5. Collaboration Activities
8.3. Value Chain
8.3.1. Raw Material Suppliers
8.3.2. List of Manufacturers
8.3.3. List of Distributors
8.4. COVID-19 Crisis – Impact Assessment
8.4.1. Current Statistics
8.4.2. Short-Mid-Long Term Outlook
8.4.3. Likely Rebound
8.5. Market Dynamics
8.5.1. Drivers
8.5.2. Restraints
8.5.3. Opportunity Analysis
8.5.4. Trends
9. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021
9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Type 2022–2032
9.3.1. Non-Muscle-Invasive Bladder Cancer
9.3.2. Muscle-Invasive Bladder Cancer
9.4. Market Attractiveness Analysis by Type
10. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032
10.3.1. Low-Grade Tumors
10.3.2. High-Grade Tumors
10.4. Market Attractiveness Analysis By Application
11. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021
11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021
12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia and Pacific
12.3.6. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Type
13.4.3. By Application
13.4.4. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Application
13.5.4. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants – Intensity Mapping
13.8. Drivers and Restraints – Impact Analysis
14. Latin America Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Type
14.4.3. By Application
14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Application
14.5.4. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants – Intensity Mapping
14.8. Drivers and Restraints – Impact Analysis
15. Europe Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Rest of Europe
15.4.2. By Type
15.4.3. By Application
15.4.4. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Application
15.5.4. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants – Intensity Mapping
15.8. Drivers and Restraints – Impact Analysis
16. South Asia and Pacific Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. India
16.4.1.2. ASEAN
16.4.1.3. Oceania
16.4.1.4. Rest of South Asia & Pacific
16.4.2. By Type
16.4.3. By Application
16.4.4. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Type
16.5.3. By Application
16.5.4. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants – Intensity Mapping
16.8. Drivers and Restraints – Impact Analysis
17. East Asia Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.2. By Type
17.4.3. By Application
17.4.4. By Distribution Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Type
17.5.3. By Application
17.5.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants – Intensity Mapping
17.8. Drivers and Restraints – Impact Analysis
18. Middle East and Africa Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021
18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
18.4.1. By Country
18.4.1.1. GCC Countries
18.4.1.2. Turkey
18.4.1.3. Northern Africa
18.4.1.4. South Africa
18.4.1.5. Rest of Middle East and Africa
18.4.2. By Type
18.4.3. By Application
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Type
18.5.3. By Application
18.5.4. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants – Intensity Mapping
18.8. Drivers and Restraints – Impact Analysis
19. Emerging Countries Bladder Cancer Treatment Drugs Market Analysis
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Bladder Cancer Treatment Drugs Market Analysis
19.2.1. By Type
19.2.2. By Application
19.2.3. By Distribution Channel
19.3. Canada Bladder Cancer Treatment Drugs Market Analysis
19.3.1. By Type
19.3.2. By Application
19.3.3. By Distribution Channel
19.4. Mexico Bladder Cancer Treatment Drugs Market Analysis
19.4.1. By Type
19.4.2. By Application
19.4.3. By Distribution Channel
19.5. Brazil Bladder Cancer Treatment Drugs Market Analysis
19.5.1. By Type
19.5.2. By Application
19.5.3. By Distribution Channel
19.6. Germany Bladder Cancer Treatment Drugs Market Analysis
19.6.1. By Type
19.6.2. By Application
19.6.3. By Distribution Channel
19.7. Italy Bladder Cancer Treatment Drugs Market Analysis
19.7.1. By Type
19.7.2. By Application
19.7.3. By Distribution Channel
19.8. France Bladder Cancer Treatment Drugs Market Analysis
19.8.1. By Type
19.8.2. By Application
19.8.3. By Distribution Channel
19.9. U.K. Bladder Cancer Treatment Drugs Market Analysis
19.9.1. By Type
19.9.2. By Application
19.9.3. By Distribution Channel
19.10. Spain Bladder Cancer Treatment Drugs Market Analysis
19.10.1. By Type
19.10.2. By Application
19.10.3. By Distribution Channel
19.11. BENELUX Bladder Cancer Treatment Drugs Market Analysis
19.11.1. By Type
19.11.2. By Application
19.11.3. By Distribution Channel
19.12. Russia Bladder Cancer Treatment Drugs Market Analysis
19.12.1. By Type
19.12.2. By Application
19.12.3. By Distribution Channel
19.13. China Bladder Cancer Treatment Drugs Market Analysis
19.13.1. By Type
19.13.2. By Application
19.13.3. By Distribution Channel
19.14. Japan Bladder Cancer Treatment Drugs Market Analysis
19.14.1. By Type
19.14.2. By Application
19.14.3. By Distribution Channel
19.15. S. Korea Bladder Cancer Treatment Drugs Market Analysis
19.15.1. By Type
19.15.2. By Application
19.15.3. By Distribution Channel
19.16. India Bladder Cancer Treatment Drugs Market Analysis
19.16.1. By Type
19.16.2. By Application
19.16.3. By Distribution Channel
19.17. ASEAN Bladder Cancer Treatment Drugs Market Analysis
19.17.1. By Type
19.17.2. By Application
19.17.3. By Distribution Channel
19.18. Australia and New Zealand Bladder Cancer Treatment Drugs Market Analysis
19.18.1. By Type
19.18.2. By Application
19.18.3. By Distribution Channel
19.19. GCC Countries Bladder Cancer Treatment Drugs Market Analysis
19.19.1. By Type
19.19.2. By Application
19.19.3. By Distribution Channel
19.20. Turkey Bladder Cancer Treatment Drugs Market Analysis
19.20.1. By Type
19.20.2. By Application
19.20.3. By Distribution Channel
19.21. Northern Africa Bladder Cancer Treatment Drugs Market Analysis
19.21.1. By Type
19.21.2. By Application
19.21.3. By Distribution Channel
19.22. South Africa Bladder Cancer Treatment Drugs Market Analysis
19.22.1. By Type
19.22.2. By Application
19.22.3. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. GlaxoSmithKline plc
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.2. Novartis International AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.3. Sanofi S.A
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.4. Pfizer Inc.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.5. Eli Lilly and Co
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.6. AstraZeneca plc
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.7. Bristol-Myers Squibb
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.8. F., Celgene Corporation
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.9. Hoffmann-La Roche AG
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology